Compare KYN & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYN | WGS |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 2004 | 2020 |
| Metric | KYN | WGS |
|---|---|---|
| Price | $14.25 | $67.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $93.50 |
| AVG Volume (30 Days) | 316.4K | ★ 747.4K |
| Earning Date | 01-01-0001 | 10-27-2026 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $427,539,000.00 |
| Revenue This Year | N/A | $12.70 |
| Revenue Next Year | N/A | $24.31 |
| P/E Ratio | $20.75 | ★ N/A |
| Revenue Growth | N/A | ★ 39.97 |
| 52 Week Low | $11.31 | $32.21 |
| 52 Week High | $15.17 | $170.87 |
| Indicator | KYN | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 34.41 |
| Support Level | $13.59 | $56.36 |
| Resistance Level | $14.35 | $73.21 |
| Average True Range (ATR) | 0.24 | 6.00 |
| MACD | 0.04 | -2.31 |
| Stochastic Oscillator | 79.38 | 10.43 |
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.